Healio

Laru-zova shows safety, low luminance visual acuity gains in X-linked retinitis pigmentosa

Please provide your email address to receive an email when new articles are posted on . Laru-zova demonstrated a positive safety profile and early efficacy in improving low luminance visual acuity in ...
Healio

Low luminance reduces face recognition, especially among those with central vision loss

Please provide your email address to receive an email when new articles are posted on . Facial identity discrimination accuracy decreased by 20.4% under low luminance for those with central vision ...
Nasdaq

Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025

LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a ...
MedPage Today

Geographic Atrophy: The Effects of Lesion Location and Functional Deficits

GA lesions, which form on the retina due to degeneration of pigment epithelium and photoreceptors, significantly impact daily functioning. This analysis assessed how functional and structural ...
Seeking Alpha

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

Vonaprument Has the Potential to Be the First Treatment Approved in Europe and the U.S. for Dry AMD with Geographic Atrophy Based on Protection of Visual Acuity and Visual Structures BRISBANE, Calif., ...
Business Insider

Beacon Therapeutics Announces Positive Interim 9+ Month Results from DAWN Trial and 36-Month Phase 2 SKYLINE Trial Data for Laru-zova in Patients with X-linked Retinitis ...

Data showed sustained improvements across several key measures of visual function, including low luminance visual acuity and microperimetry Laru-zova was generally well-tolerated by SKYLINE ...